Bioanalytical Testing CROs in China

Leading global pharmaceutical and medical device open-access capability and technology platform. WuXi AppTec provides services spanning from discovery through manufacturing across small molecules, biologics, and cell/gene therapies.

Nanjing-based clinical CRO and Pharmaron subsidiary providing one-stop clinical development services in China including regulatory affairs, clinical operations, pharmacovigilance, and bioanalysis.

Labcorp Drug Development's Chinese laboratory providing preclinical safety assessment, bioanalytical services, and clinical trial support for NMPA regulatory submissions.

Shanghai-based preclinical CRO providing in vivo pharmacology, toxicology, DMPK, and bioanalytical services with specialized PDX platforms for oncology drug development.

Chinese operations of Frontage Laboratories providing bioanalytical services, ADME/PK studies, and analytical chemistry from GLP-compliant laboratories in Shanghai and Suzhou.

Chinese preclinical CRO providing GLP-compliant safety evaluation, pharmacokinetics, efficacy studies, and drug metabolism studies with comprehensive NHP and rodent capabilities.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Chinese CRO and CDMO providing drug discovery chemistry, DMPK, analytical services, and clinical trial manufacturing from Shanghai and Chengdu operations.

Clinical division of WuXi AppTec providing end-to-end Phase I-IV clinical trial services across China and Asia with expertise in NMPA, FDA and EMA regulatory submissions.